Table 4

Association between anti-Ro52/TRIM21 antibodies and other SSc-related autoantibodies

Antibody

Prevalence

(N = 963)

Anti-Ro52 antibody positive

(n = 194)

Anti-Ro52 antibody negative

(n = 769)

P values

Mean anti-Ro52/TRIM21 titer

(U/ml)

n

%

n

%

n

%

Centromere

334

34.76%

78

40.41%

256

33.33%

NS

1,098.64

Topoisomerase I

150

15.58%

19

9.79%

131

17.04%

0.0129

763.28

RNApolIII

144

18.58%

23

15.75%

121

19.24%

NS

1,164.47

Pm/Scl

53

6.84%

10

6.85%

43

6.84%

NS

1,381.13

U1 RNP

59

6.13%

20

10.31%

39

5.07%

0.0066

2,099.45

CENP-B

285

35.58%

64

42.95%

221

33.90%

0.0372

1,098.86

CENP-A

275

34.33%

61

40.94%

214

32.82%

NS

1,019.93

Ro60

53

5.50%

40

20.62%

13

1.69%

< 0.0001

5,530.66

SS-B/La

26

2.70%

18

9.28%

8

1.04%

< 0.0001

6,003.88

Jo-1

6

0.62%

4

2.06%

2

0.26%

0.0171

4,412.83

Sm

39

4.05%

13

6.70%

26

3.38%

0.0361

1,482.09

Ribosomal P

14

1.45%

3

1.55%

11

1.43%

NS

2,088.14

Chromatin

44

4.57%

10

5.15%

34

4.42%

NS

1,162.30

NS, not significant.

Hudson et al. Arthritis Research & Therapy 2012 14:R50   doi:10.1186/ar3763